|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 姜黄素对DSS诱导溃疡性结肠炎小鼠T淋巴细胞亚群及BTLA表达的影响显示文摘目的探讨姜黄素对DSS诱导溃疡性结肠炎小鼠T淋巴细胞亚群及BTLA表达的影响。方法采用葡聚糖硫酸钠法(DSS)制备UC小鼠模型,小鼠随机分为4组:对照组、DSS模型组、地塞米松组、姜黄素组,通过腹腔注射药物作用,应用流式细胞仪检测T淋巴细胞亚群和细胞因子表达的百分率。结果姜黄素组与DSS模型组比较,小鼠外周血CD4+细胞数明显升高,CD8+细胞数明显降低,CD4+/CD8+比值明显升高(Р<0.01);小鼠脾脏Th1+细胞、Tc1+细胞比例和Th1+/Th2+比值、Tc1+/Tc2+比值明显降低,而Th2+细胞明显升高(P<0.05);小鼠外周血、脾脏CD4+T细胞上BLTA+的表达明显增高(P<0.01)。结论姜黄素对DSS诱导UC小鼠CD4+T细胞亚群及BTLA表达显著升高,可能是通过调节CD4+/CD8+T淋巴细胞亚群间的平衡,抑制Th1型/Tc1型细胞分化,促使CD4 T淋巴细胞表面BTLA表达上调,降低免疫反应,发挥抗炎及治疗UC作用。 | 祝斌 蔡康荣 姚晓敏 安博然 | 2015 | 齐齐哈尔医学院学报2015，36，29： | 8 |
| 2 | B cell depletion in treating primary biliary cirrhosis:Pros and cons显示文摘Primary biliary cirrhosis (PBC) is a progressive autoim- mune liver disease of unknown etiology that affects almost exclusively women.Ursodeoxycholic acid (UDCA) is currently the only approved drug by Food and Drug Administration for patients with PBC.Although the precise pathogenesis of PBC remains unclear,it has been postulated that many cell populations,including B cells,are involved in the ongoing inflammatory process,which implicates,not surprisingly,a potential thera- peutic target of depleting B cell to treat this disorder.Rituximab is a chimeric anti-CD20 monoclonal antibody that has been approved for the treatment of lymphoma and some autoimmune diseases such as rheumatoid arthritis.Whether it is effective in the treatment of PBC has not been evaluated.Recently,Tsuda et al [1] demon- strated that B cell depletion with rituximab significantly reduced the number of anti-mitochondrial antibodies (AMA)-producing B cells,AMA titers,the plasma levels of immunoglobulins (IgA,IgM and IgG) as well as se- rum alkaline phosphatase,and it was well tolerated by all the treated patients with no serious adverse events.This observation provides a novel treatment option for the patients with PBC who have incomplete response to UDCA. | Yu-Feng Yin Xuan Zhang | 2012 | World Journal of Gastroenterology2012，18，30： | 4 |
| 3 | Spontaneous free perforation of the small intestine in adults显示文摘Spontaneous free perforation of the small intestine is uncommon,especially if there is no prior history of visceral trauma.However,free,even recurrent,perforation may complicate a defined and established clinical disorder,such as Crohn’s disease.In addition,free perforation may be the initial clinical presentation of an occult intestinal disorder,such as a lymphoma complicating celiac disease,causing diffuse peritonitis and an acute abdomen.Initial diagnosis of the precise cause may be difficult,but now has been aided by computerized tomographic imaging.The site of perforation may be helpful in defining a cause(e.g.,ileal perforation in Crohn’s disease,jejunal perforation in celiac disease,complicated by lymphoma or collagenous sprue).Urgent surgical intervention,however,is usually required for precise diagnosis and treatment.During evaluation,an expanding list of other possible causes should be considered,even after surgery,as subsequent management may be affected.Free perforation may not only complicate an established intestinal disorder,but also a new acute process(e.g.,caused by different infectious agents)or a longstanding and unrecognized disorder(e.g.,congenital,metabolic and vascular causes).Moreover,new endoscopic therapeutic and medical therapies,including use of emerging novel biological agents,have been complicated by intestinal perforation.Recent studies also support the hypothesis that perforation of the small intestine may be genetically-based with different mutations causing altered connective tissue structure,synthesis and repair. | Hugh James Freeman | 2014 | World Journal of Gastroenterology2014，20，29： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员